Extract
In the recent correspondence “Is high-dose glucocorticoid beneficial in COVID-19?” Muthuet al. raised some issues related to our recent clinical trial “Intravenous methylprednisolone pulse as a treatment for hospitalised severe COVID-19 patients: results from a randomised controlled clinical trial” [1]. This provides a welcome opportunity to further explain the outcome of using a high dose of glucocorticoid for the treatment of severe COVID-19 patients.
Abstract
Our clinical trial supports the beneficial use of a high dose of methylprednisolone for the treatment of severe COVID-19 patients.
Footnotes
Conflict of interest: Dr. Edalatifard has nothing to disclose.
Conflict of interest: Dr. Akhtari has nothing to disclose.
Conflict of interest: Dr. Salehi has nothing to disclose.
Conflict of interest: Dr. Farhadi has nothing to disclose.
Conflict of interest: Dr. Jamshidi has nothing to disclose.
Conflict of interest: Dr. Mahmoudi has nothing to disclose.
利益冲突:Rostamian博士无关disclose.
- ReceivedFebruary 2, 2021.
- AcceptedFebruary 11, 2021.
- Copyright ©The authors 2021.
This version is distributed under the terms of the Creative Commons Attribution Non-Commercial Licence 4.0. For commercial reproduction rights and permissions contactpermissions{at}ersnet.org